Dr. Xiaohui Lu is an Executive Director of Analytical Development at Ultragenyx, heading the analytical effort for the company’s gene therapy programs for the past 4 years. Prior to joining Ultragenyx, Dr. Lu held various positions at CRISPR Therapeutics, Biogen, and Ariad Pharmaceuticals. Dr. Lu received his Ph.D. in Biochemistry from Dartmouth Medical School and had post-doctoral training at the Whitehead Institute.